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Introduction
Fluoroquinolone antibiotics such as ciprofloxacin are widely used antimicrobial agents displaying broad spectrum activity against both gram positive and gram negative bacteria. At physiological pH (7.4), ciprofloxacin exists predominantly as a zwitterion, with a shift towards the cationic form at pH 6.5 (Sorgel & Kinzig, 1993) . The octanol water partition coefficient (logP) value for this compound is -1.08 suggesting moderately hydrophilic properties which would serve to reduce lipid partitioning and passive transcellular absorptive permeability (Zhao et al, 2002) . In agreement with this assessment, ciprofloxacin has been classified as a low permeability compound (Volpe, 2004; Zakelj et al, 2006) . In vivo it displays variable oral bioavailability of between 50-80% (Sorgel et al, 1989a) . Ciprofloxacin plasma clearance in vivo is predominately renal (Jaehde et al, 1989; Rohwedder et al, 1990) but is also subject to intestinal elimination (Sorgel et al, 1989b (Sorgel et al, & 1991 without undergoing significant metabolism (Sorgel et al, 1989b) . The intestinal elimination pathway becomes increasingly important for patients with reduced renal function (Rohwedder et al, 1990 ).
The mechanisms responsible for ciprofloxacin secretion in the gut have been widely investigated. As has been recently highlighted, many fluoroquinolones are subject to ATP-binding cassette (ABC) transporter-mediated efflux (Alvarez et al, 2008) . Previously, Griffiths et al (1993) demonstrated saturable ATP-dependent secretory transport in human intestinal Caco-2 cells with a number of fluoroquinolones sharing a common secretory pathway (Griffith et al, 1993 (Griffith et al, & 1994 .
Measurements of basolateral and apical transport suggested the existence of distinct transporters at either membrane domain (Griffith et al, 1994) though transport characteristics were distinct from those of vinblastine, a known P-glycoprotein (Pgp) This article has not been copyedited and formatted. The final version may differ from this version. (Cavet et al, 1997) . Lowes and Simmons (2002) confirmed the lack of involvement of MDR1 in ciprofloxacin secretion using wild-type and MDR1 transfected MDCKII cells. More recently, Merino et al (2006) have shown ciprofloxacin secretion using murine bcrp1-transfected MDCKII epithelial layers whereas in human BCRP-transfected MDCKII cells ciprofloxacin secretion was evident only at extended incubation times. In both cases, net secretion was inhibited by the selective BCRP inhibitor Ko143 (Merino et al, 2006) . In bcrp knock-out mice ciprofloxacin plasma concentrations were 2-fold greater following oral administration suggesting the significant involvement of bcrp1 in modulating systemic drug levels (Merino et al, 2006) .
Ciprofloxacin transport may occur through additional ABC transporters. A recent investigation into bacterial resistance to fluoroquinolones has studied the impact of MRP transporters on ciprofloxacin accumulation in murine J774 macrophages (Marquez et al, 2009) . It was noted that the resistant populations displayed increased expression of both Mrp2 and Mrp4 and reduced levels of intracellular ciprofloxacin. Using siRNA to selectively deplete either MRP2 or 4 it was shown that Mrp4 alone acts to reduce ciprofloxacin accumulation (Marquez et al, 2009 ).
There are few direct measurements of ciprofloxacin secretion across intestinal segments in vitro. An active secretion of ciprofloxacin was observed in rat small intestinal tissue mounted in Ussing chambers, with higher secretory flux being observed in distal compared to proximal small intestine (Zakelj et al, 2006) . However, Rodriguez-Ibanez et al, (2006) demonstrated no regional variation in absorptive ciprofloxacin permeability in the rat using the in situ gut loop technique.
There are no ex-vivo measurements of ciprofloxacin transport in human intestine and This article has not been copyedited and formatted. The final version may differ from this version. The objectives of the current study were twofold; first the question whether BCRP alone may mediate intestinal secretion of ciprofloxacin was addressed by the use of mBcrp1, hBCRP and hMRP4 transfected cell lines, together with Caco-2 epithelial layers in which the selective BCRP inhibitor, Ko143 was utilised.
Secondly the extent of BCRP-mediated ciprofloxacin secretion by human and rat intestine, including investigation of regional variation in ciprofloxacin efflux in the rat has been determined in excised intestinal tissue mounted in Ussing chambers.
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Ussing chamber experiments
Ethical approval for the use of human intestinal samples from patients undergoing pancreatoduodenectomy to remove tumours of the head of the pancreas surplus to histopathological requirements was granted (IRAS reference: 09/H1006/2).
Human tissue samples were collected from 3 such male patients with their informed consent. None of the patients had previously undergone radio-or chemotherapy prior to surgery. Blood perfusion of the intestine was maintained until the moment of excision. Approximately 10cm of proximal jejunum was removed and immediately placed in ice-cold Krebs Bicarbonate Ringer, pre-saturated with carbogen. The tissue was then transported from the hospital operating theatre to the laboratories at AstraZeneca. The mean time period between excision of intestinal tissue and arrival at the laboratory was 88 ± 19 minutes. Tissue was prepared for use in the Ussing chambers as previously described (Haslam et al, 2011 -23, revised 1985) . For surgical procedures, rats were anaesthetised using inhaled isofluorane (induction 5%, 2 L/min and thereafter 3%, 0.7 L/min).
Following abdominal incisions, intestinal lumens were occluded by thin cotton thread proximal to the sections of tissue taken from duodenum (within 15cm proximal to the pyloric sphincter), jejunum (5 cm distal to the ligament of Treitz), ileum (2 cm proxmal to the ileo-caecal junction) and colon (2 cm distal to the caecum). The segments were placed in a chamber containing ice-cold KBR perfused with carbogen for 30 minutes. Removal by dissection of the serosal layer of the duodenal, jejunal and ileal sections and the serosa and muscularis externa of the colonic sections was performed with the aid of a stereo microscope (Wild M8) and a light source (Schott KL 1500).
Intestinal segments (rat and human) were mounted as flat sheets in a modified
Ussing chamber (Harvard Navicyte). The exposed tissue surface area was 0.64 cm 2 or 1.78 cm 2 for rat and human sections, respectively. A 4 electrode system was used for recording electrical parameters. This consisted of 2 x Ag/AgCl electrodes for PD measurement and 2 x Ag/AgCl electrodes for current passage. Asymmetry in the PD sensing electrodes was zeroed prior to tissue mounting. Correction for the series fluid resistance was also made in assembled chambers prior to tissue mounting.
After 30-40 minutes' equilibration at 37 o C, mean PD values were comparable with previous studies (Polentarutti et al., 1999) , indicative of viable tissue segments.
To initiate experiments, the KBR in "donor" or "receiver" wells was replaced with 5 ml of KBR containing ciprofloxacin (1-100 (Soderholm et al, 1998) . P a, b or app is expressed in cm/s.
Cell culture
All cell culture was performed in a class II laminar flow hood (Safeflow1. and Penicillin/Streptomycin (1% v/v).
Transepithelial transport experiments in cultured monolayers
Bi-directional transepithelial transport experiments were performed using Caco-2 cell monolayers. Table 1 shows detection of hBCRP expression in both Caco-2 cell strains though hBCRP mRNA expression relative to GAPDH in low passage
Caco-2 cells is greater than that seen in high passage cells.
The pharmacological sensitivity of ciprofloxacin secretion by bcrp1-MDCKII and Caco-2 cell layers was assessed. Ko143, a potent and specific BCRP inhibitor (Allen et al., 2002) .hr -1 , n =3, P < 0.05, Figure 2A ). Ko143 (1μM) reduced net ciprofloxacin secretion in low passage Caco-2 cells from 0. Previously we have shown that the anion transport inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS) at 0.4 mM may inhibit ciprofloxacin secretion across Caco-2 monolayers (Cavet et al., 1997 .hr -1 , n = 3, P < 0.05) and low passage Caco-2 monolayers (from 0.39 ± 0.06 nmol.cm -2 .hr -1 to 0.14 ± 0.03 nmol.cm -2
.hr -1 , n = 3, P < 0.05) suggesting that DIDS is therefore not a definitive pharmacological agent with respect to the inhibition of ciprofloxacin secretion.
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was without effect ( Figure 2B&C ), confirming no MRP(4) involvement in ciprofloxacin secretion in this model system. MK571 had no significant effect on ciprofloxacin secretion in bcrp1-MDCKII cells (Figure 2A ). Figure 4 shows that excised rat small intestine is able to maintain a substantial net ciprofloxacin secretion from basal (blood) to apical (lumen) solutions.
Ciprofloxacin secretion in rat intestinal tissue
Asymmetric permeability was noted in all regions of the small intestine (duodenum, jejunum and ileum) but no net secretion observed in the colon. Figure 4 (inset) compares the kinetics of net ciprofloxacin secretion (Jnet) in bcrp1-MDCKII epithelia with those for rat ileum. The maximal secretory capacity of rat ileum is 2 fold greater than bcrp1-transfected MDCKII cells (Table 2 ). For comparison, kinetic data for ciprofloxacin secretion by Caco-2 intestinal epithelia are shown (Table 2) 
ABC-Transporter mRNA expression along the rat intestinal tract
Intestinal segmental variations in the expression of mdr1a, mrp4 and bcrp mRNA was determined by quantitative PCR (Figure 6 ). For bcrp the greatest level of This article has not been copyedited and formatted. The final version may differ from this version. Figure 6 ). Mdr1a, Bcrp1 and Mrp4 all showed a similar aboral increase in expression, with a peak evident in the ileum (P < 0.05, n=3-5 animals, relative to duodenum). Expression of all transcripts was lower in the colon compared to the ileum. These results confirm data reported in previous studies for bcrp (MacLean et al, 2008) . In contrast to this data, the same authors have reported higher Mdr1a expression in the colon, than in the ileum, although this data was not significant. Stephens et al (2002) reported higher Pgp protein levels in the ileum and distal colon, than in proximal colon.
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Ciprofloxacin secretion in human intestinal tissue
Discussion
Previous studies have highlighted the importance of active efflux transporters in the secretion of ciprofloxacin and other fluroquinolones into the intestinal lumen (Cavet et al, 1997; Lowes and Simmons, 2002) , a clinically important route for elimination (Sorgel et al, 1989 (Sorgel et al, , 1991 . We have confirmed that murine bcrp1
mediates active efflux of ciprofloxacin across the apical membrane of bcrp1-overexpressing MDCKII cell monolayers, which showed a significant increase in secretion relative to wild-type cells (Merino et al, 2006) . Comparative studies have shown lower levels of substrate efflux in BCRP-MDCKII cells as compared to bcrp1-MDCKII cells for a number of compounds, including benzimidazoles, fluoroquinolones, troglitazone sulphate and mitoxantrone (Merino et al, 2005 (Merino et al, , 2006 Enokizono et al, 2007; An & Morris, 2010) . The original hBCRP-MDCKII cell line (Pavek et al, 2005) was generated from a full-length human BCRP cDNA gifted from Susan Bates (Miyake et al, 1999 , Ozvegy et al, 2001 ). The hBCRP transfected to form the hBCRP-MDCKII cell-line is the wild type with arginine at position 482 variant (Pavek et al, 2005 ). An R482G mutation is acquired previously reported values for bcrp inhibition (Allen et al, 2002; Muenster et al, 2008) . Furthermore, the net secretion of ciprofloxacin was completely abolished by the specific BCRP inhibitor Ko143, in contrast to the partial inhibition evident with CsA and DIDS, Pgp/BCRP and anion exchange inhibitors, respectively. Ko143 inhibition is therefore a useful tool for defining BCRP-mediated transport in intact epithelial layers.
As ciprofloxacin shows net secretory transport in Caco-2 cell monolayers, it is apparent that an interaction with a human efflux transporter(s) exist. Secretion of ciprofloxacin in low passage Caco-2 cells is only partially reduced by Ko143 (53%).
The inability to fully inhibit net ciprofloxacin flux in Caco-2 cells indicates that additional and distinct mechanisms other than BCRP exist to maintain active ciprofloxacin secretion. Evidence for a distinct mechanism can be found in the data from the high passage Caco-2 cells, in which Ko143-insensitive ciprofloxacin secretion is maintained in the presence of only minor expression of BCRP mRNA (relative to GAPDH).
This article has not been copyedited and formatted. The final version may differ from this version. We therefore investigated the role of MRP4 by looking at ciprofloxacin uptake into MRP4 overexpressing HEK-293 cells (Wielinga et al, 2002) . There was a significant reduction in ciprofloxacin accumulation in the MRP4-HEK cells relative to the wildtype controls. In addition, an increase in ciprofloxacin accumulation (inhibition of MRP-mediated efflux), was evident following the inclusion of the known MRP (4) antagonist MK571 (Van Aubel et al, 2002; Reid et al, 2003; Wu et al, 2005) , in both the wild-type and transfected cells. The impact of MK571 in both wild-type and transfected cell models suggested that HEK293 cells express endogenous levels of MRP4, which has been confirmed by qPCR analysis. As Ko143 does not affect accumulation, it is evident that MRP4 is responsible for mediating the export of ciprofloxacin from these cells (limiting cellular accumulation).
In low passage Caco-2 cells, MRP4 mRNA expression was also confirmed. This study has for the first time also confirmed active secretion of ciprofloxacin in the human intestine using the Ussing Chamber technique. Absorptive permeability is of a similar magnitide to the rat duodenum; however the secretory component is larger, giving rise to a higher efflux ratio. Although absorptive permeability was very similar for each individual donor, there was considerable variability in secretory ciprofloxacin movement (Table 3 ). This is in contrast to the data generated for the dual Pgp/BCRP substrate, prazosin, which displays substantially lower variability. Addition of the specific BCRP inhibitor Ko143 reduces net ciprofloxacin secretion by 113%, an effect that is statistically significant despite the inter-patient variability in ciprofloxacin transport data. It may be concluded that, as with the rat small intestine, ciprofloxacin secretion is likely to be mediated predominantly via BCRP in the human jejunum. Further experiments are required to substantiate the Ko143-independent ciprofloxacin secretory component suggested by the data from donor 2. As a substantial increase in absorptive permeability may also be observed following Ko143 inhibition, we suggest that BCRP may play a role in partially limiting human absorption of ciprofloxacin in vivo.
In conclusion, this study has demonstrated that ciprofloxacin is likely to be a substrate for BCRP in human intestinal cells (Caco-2), as indicated by sensitivity to Ko143 inhibition. It is also likely that alternative transport pathways exist. Both rodent and human intestine display active secretion of ciprofloxacin which is This article has not been copyedited and formatted. The final version may differ from this version. 
